| Document |
Document Title |
|
WO/2021/153786A1 |
The present invention provides a compound having an excellent control effect against pests. A compound represented by formula (1) of the present invention (in the formula, Q represents a group indicated by Q1 or a group indicated by Q2 (...
|
|
WO/2021/154904A1 |
The present disclosure encompasses solid state forms of Mavacamten, in embodiments crystalline polymorphs of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/155185A1 |
The present invention provides aminopyrimidinylaminobenzonitrile compounds that inhibit the activity of never in mitosis gene A-related kinase 2 (NEK2) and are useful in the treatment of diseases related to activity of NEK2, including ca...
|
|
WO/2021/146543A1 |
Provided herein are compounds having the following structural formula, wherein values for the variables are as described herein. Also provided are pharmaceutical compositions of the compounds, as well as methods of using the compounds to...
|
|
WO/2021/139482A1 |
The present invention belongs to the technical field of pesticides, and in particular relates to a carboxylic acid derivative-substituted imino aryl compound, a preparation method therefor, a herbicidal composition and use thereof. The c...
|
|
WO/2021/140418A1 |
Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE) by administering to a subject in need thereof, a combination of a dipeptidyl peptidase 4 (DPP-4) inhibitor and a compound of Formul...
|
|
WO/2021/139748A1 |
Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KR...
|
|
WO/2021/135517A1 |
The present application belongs to the technical field of organic materials, and specifically provided therein is an organic compound. The compound is a structure composed by using an adamantyl group as the core and by linking two nitrog...
|
|
WO/2021/136238A1 |
Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen o...
|
|
WO/2021/135183A1 |
The present application relates to the technical field of organic materials, and provides an organic compound. A novel compound for an organic electroluminescent device is obtained by bonding and combining an adamantane spiro fluorenyl g...
|
|
WO/2021/130776A1 |
The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3 methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6dihydropyrimidin-1(2H)-yl]-...
|
|
WO/2021/128764A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic device. The structure of the nitrogen-containing compound is as shown in a...
|
|
WO/2021/133509A1 |
The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and o...
|
|
WO/2021/129561A1 |
A cyano-substituted pyridine and cyano-substituted pyrimidine compound and a preparation method therefor and an application thereof, which specifically relate to a compound represented by formula (I) and an isomer, a hydrate, a solvate, ...
|
|
WO/2021/125803A1 |
The present invention relates to a novel pyrimidin derivative and a use thereof. The pyrimidin derivative has excellent MLK3 inhibitory activity and LRRK2 inhibitory activity and thus can be utilized in a pharmaceutical composition for p...
|
|
WO/2021/127071A1 |
The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compos...
|
|
WO/2021/122249A1 |
Process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is reacted with a cyclic compound comprising a cyclic compound having at least one nitrogen as ring member, bearing a substitutable hydrogen residue (cyclic...
|
|
WO/2021/123174A1 |
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cogni...
|
|
WO/2020/252581A9 |
The present application provides a colloid drug aggregate composition and methods of use and manufacture thereof. While the formation of colloidal aggregates leads to artifacts in early drug discovery, their composition makes them attrac...
|
|
WO/2021/125834A1 |
The present invention provides: a novel compound capable of improving the light-emitting efficiency, stability and lifespan of an element; an organic electrical element using same; and an electronic device thereof.
|
|
WO/2021/127273A1 |
Described herein are compounds of formulae (I), (lla) and (Mb) as prolyl hydroxylase inhibitors, HIF-lalpha stabilizers and PGK up regulators for use in treating inflammatory diseases, cancer or infections: Preferred compounds are e.g. t...
|
|
WO/2021/116709A1 |
Compounds and their Use for the Treatment of α1-Antitrypsin Deficiency The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α1...
|
|
WO/2021/114691A1 |
The present invention relates to a nitrogen-containing ring-fused compound, a preparation method therefor and a use thereof. Specifically, the present invention relates to a compound having a structure represented by formula (X), a stere...
|
|
WO/2021/118086A2 |
The present invention relates to: a novel compound having excellent carrier transport capability, luminescence capability, and thermal stability; and an organic electroluminescent device which, by comprising same in at least one organic ...
|
|
WO/2021/117846A1 |
The purpose of the present invention is to provide a compound having an inhibitory activity against a PDGF receptor kinase. The present invention includes, for example, a compound represented by formula [1] or a pharmaceutically accept...
|
|
WO/2021/116706A1 |
The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α1-antitrypsin (A1AT), and may be used in the treatment of a disease or di...
|
|
WO/2021/116050A1 |
The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/110177A1 |
Provided are a rhein derivative and antiviral use thereof, belonging to new drug development technologies. The rhein derivative has a structure as shown in general formula (I) or formula (II), and the experimental data shows that it has ...
|
|
WO/2021/113282A1 |
A method for preparing a compound of Formula 1 and compounds therefrom, comprising treating a compound of Formula 2 with a compound of Formula 3 and reacting the resulting intermediate of Formula 4 with a compound of Formula 5 (or a salt...
|
|
WO/2021/113266A1 |
Disclosed herein are methods, pharmaceutical combinations, and dosage combinations for the prevention or treatment of cognitive disorders with the administration of a therapeutic effective amount of trapidil, a derivative, a metabolite, ...
|
|
WO/2021/111311A2 |
The present invention provides novel adamantane derivatives as inhibitors of a focal adhesion kinase, pharmaceutically acceptable salts thereof, stereoisomer thereof, a hydrate or solvate thereof, and a pharmaceutical composition compris...
|
|
WO/2021/113689A1 |
The present disclosure provides SPAK/OSR inhibitors. In certain embodiments, the compounds of the disclosure can be used to treat, ameliorate, and/or prevent certain cancers in a subject.
|
|
WO/2021/113808A1 |
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating dis...
|
|
WO/2021/108683A1 |
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological proces...
|
|
WO/2021/104363A1 |
Disclosed are a composition containing an aromatic heterocyclic compound in an amorphous form, and a preparation method therefor and a use thereof. Specifically, disclosed is a composition containing a compound of formula (1) and a carri...
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102567A1 |
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors....
|
|
WO/2021/106947A1 |
Provided are a compound represented by formula (1) or a pharmacologically acceptable salt thereof, and an antitrypanosomal drug containing the same as an active ingredient. In formula (1), X is NH or CH2, R1 is a hydrogen atom, an alkoxy...
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2021/105908A1 |
The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R1a, R2a, R3a, A1, A2, A3, R1b, R2b, R3b, B1, and B2 are as set forth in the specification, as well as to methods for their preparat...
|
|
WO/2021/107657A1 |
The present invention relates to a novel quinazoline derivative compound and a use thereof and, more specifically, to a novel quinazoline derivative compound of the following chemical formula 1 having inhibitory activity against a bromod...
|
|
WO/2021/103256A1 |
The present invention provides a continuous synthesis method for a 2-chloropyrimidine-4-formic acid compound. The 2-chloropyrimidine-4-formic acid compound has the structure as shown in formula I: (I), in formula I, R1 and R2 are indepen...
|
|
WO/2021/098859A1 |
An aza seven-membered ring inhibitor, and a preparation method therefor and use thereof. Specifically, a compound has a structure represented by formula (I). Disclosed are a preparation method for the compound and the use of same as a KR...
|
|
WO/2021/101264A1 |
The present invention relates to an azobenzene compound, a hologram recording composition comprising same, a hologram recording medium, a hologram recording material using same, and a method for hologram recording or hologram re-recordin...
|
|
WO/2021/101255A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to: an organic compound having excellent heat resistance, carrier transport capability, luminescence ca...
|
|
WO/2021/099842A1 |
Provided herein are pentafluorobenzenesulfonamide compounds of Formula (I), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases. These compounds are covalent small mol...
|
|
WO/2021/097110A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2021/097190A1 |
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and...
|
|
WO/2021/097054A1 |
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and c...
|
|
WO/2021/092262A1 |
The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 an...
|
